Correction to: A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia (Annals of Hematology, (2018), 10.1007/s00277-018-3229-5)

1. Martínez-Cuadrón, D.
2. Boluda, B.
3. Martínez, P.
4. Bergua, J.
5. Rodríguez-Veiga, R.
6. Esteve, J.
7. Vives, S.
8. Serrano, J.
9. Vidriales, B.
10. Salamero, O.
11. Cordón, L.
12. Sempere, A.
13. Jiménez-Ubieto, A.
14. Prieto-Delgado, J.
15. Díaz-Beyá, M.
16. Garrido, A.
17. Benavente, C.
18. Pérez-Simón, J.A.
19. Moscardó, F.
20. Sanz, M.A.
21. Montesinos, P.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1007/S00277-018-3277-X GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus